Pages

Friday, April 11, 2014

Trial of heart failure medication ended early due to positive results.

The Wall Street Journal (3/31, MacLucas, Subscription Publication) reports that Novartis AG said that it has halted a study of a heart failure medication known as LCZ696 after researchers found that the medication was shown to benefit patients.

        The Bloomberg News (3/31, von Schaper) reports that investigators “followed more than 8,000 patients with a certain type of heart failure who received either the Novartis drug or enalapril, the standard treatment.” The researchers found that patients given the experimental medication “lived longer without being hospitalized than” the “group who received” enalapril.

        Reuters (3/31) explains that the trial was evaluating the new medication in individuals with reduced ejection fraction chronic heart failure

No comments:

Post a Comment